Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial
Predicting prognosis in stable angina-results from the Euro heart survey of stable angina: prospective observational study
Daly C.A., De Stavola B., Sendon J.L., et al. Predicting prognosis in stable angina-results from the Euro heart survey of stable angina: prospective observational study. BMJ 332 (2006) 262-267
The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis
Burns R.J., Gibbons R.J., Yi Q., et al. The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis. J Am Coll Cardiol 39 (2002) 30-36
Natural history of asymptomatic left ventricular systolic dysfunction in the community
Wang T.J., Evans J.C., Benjamin E.J., Levy D., LeRoy E.C., and Vasan R.S. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation 108 (2003) 977-982
European guidelines on cardiovascular disease prevention in clinical practice: executive summary
Graham I., Atar D., Borch-Johnsen K., et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 28 (2007) 2375-2414
Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease
Diaz A., Bourassa M.G., Guertin M.C., and Tardif J.C. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 26 (2005) 967-974
Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST)
Kolloch R., Legler U.F., Champion A., et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). Eur Heart J 29 (2008) 1327-1334
Heart rate lowering by specific and selective If current inhibition with ivabradine. A new therapeutic perspective in cardiovascular disease
DiFrancesco D., and Camm A.J. Heart rate lowering by specific and selective If current inhibition with ivabradine. A new therapeutic perspective in cardiovascular disease. Drugs 64 (2004) 1757-1765
Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise
Joannides R., Moore N., Iacob M., et al. Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise. Br J Clin Pharmacol 61 (2006) 127-137
A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction
Manz M., Reuter M., Lauck G., Omran H., and Jung W. A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology 100 (2003) 149-155
Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology
Camm A.J., and Lau C.P. Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology. Drugs R D 4 (2003) 83-89
Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial
Borer J.S., Fox K., Jaillon P., and Lerebours G. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation 107 (2003) 817-823
Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina
Tardif J.C., Ford I., Tendera M., Bourassa M.G., and Fox K. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 26 (2005) 2529-2536
Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular dysfunction: the morBidity-mortality EvAlUation of the If inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) Study
Fox K., Ferrari R., Tendera M., Steg P.G., and Ford I. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular dysfunction: the morBidity-mortality EvAlUation of the If inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) Study. Am Heart J 152 (2006) 860-866
The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population
The BEAUTIFUL Study Group
The BEAUTIFUL Study Group. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. Cardiology 110 (2008) 271-282
Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)
EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators
Fox K.M., and EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362 (2003) 782-788
Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial
McMurray J., Kober L., Robertson M., et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol 45 (2005) 525-530
Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial
IONA Study Group
IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 359 (2002) 1269-1275
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design
Peto R., Pike M.C., Armitage P., et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 34 (1976) 585-612
The EuroHeart Failure Survey programme-a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment
Komajda M., Follath F., Swedberg K., et al. The EuroHeart Failure Survey programme-a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 24 (2003) 464-474
Elevated heart rate and atherosclerosis: An overview of the pathogenetic mechanisms
Giannoglou G.D., Chatzizisis Y.S., Zamboulis C., Parcharidis G.E., Mikhailidis D.P., and Louridas G.E. Elevated heart rate and atherosclerosis: An overview of the pathogenetic mechanisms. Int J Cardiol 126 (2008) 302-312
Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption
Heidland U.E., and Strauer B.E. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 104 (2001) 1477-1482